Metildigoxin
Appearance
![]() | |
Clinical data | |
---|---|
Other names | 4-[(3S,5R,8R,9S,10S,12R,13S,14S)-12,14-Dihydroxy-3-[(2R,4S,5S,6R)-4-hydroxy-5-[(2S,4S,5S,6R)-4-hydroxy-5-[(2S,4S,5S,6R)-4-hydroxy-5-methoxy-6-methyl-oxan-2-yl]oxy-6-methyl-oxan-2-yl]oxy-6-methyl-oxan-2-yl]oxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-5H-furan-2-one |
AHFS/Drugs.com | International Drug Names |
Pregnancy category |
|
ATC code | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.045.705 |
Chemical and physical data | |
Formula | C42H66O14 |
Molar mass | 794.976 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Metildigoxin (INN, or medigoxin BAN, or methyldigoxin) is a cardiac glycoside,[1] a type of drug that can be used in the treatment of congestive heart failure and cardiac arrhythmia (irregular heartbeat). The substance is closely related to digoxin; it differs from the latter only by an O-methyl group on the terminal monosaccharide.
References
[edit]- ^ Hayward R, Greenwood H, Stephens J, Hamer J (January 1983). "Relationship between myocardial uptake and actions in heart failure of methyldigoxin". British Journal of Clinical Pharmacology. 15 (1): 41–8. doi:10.1111/j.1365-2125.1983.tb01461.x. PMC 1427830. PMID 6849743.